Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Upstream Bio (UPB) Receivables (2023 - 2025)

Upstream Bio has reported Receivables over the past 3 years, most recently at $2.3 million for Q4 2025.

  • Quarterly results put Receivables at $2.3 million for Q4 2025, up 96.69% from a year ago — trailing twelve months through Dec 2025 was $2.3 million (up 96.69% YoY), and the annual figure for FY2025 was $2.3 million, up 96.69%.
  • Receivables for Q4 2025 was $2.3 million at Upstream Bio, up from $2.3 million in the prior quarter.
  • Over the last five years, Receivables for UPB hit a ceiling of $2.6 million in Q2 2025 and a floor of $236000.0 in Q4 2023.
  • Median Receivables over the past 3 years was $1.5 million (2024), compared with a mean of $1.5 million.
  • Biggest five-year swings in Receivables: surged 400.0% in 2024 and later soared 96.69% in 2025.
  • Upstream Bio's Receivables stood at $236000.0 in 2023, then surged by 400.0% to $1.2 million in 2024, then skyrocketed by 96.69% to $2.3 million in 2025.
  • The last three reported values for Receivables were $2.3 million (Q4 2025), $2.3 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.